Consolidated Statutes and Regulations
Consolidated Statutes
Consolidated Regulations
Annual Statutes and Regulations
Annual Statutes
Annual Regulations
Additional information
Québec Official Publisher
What’s new?
Information note
Policy of the Minister of Justice
Laws: Amendments
Laws: Provisions not in force
Laws: Provisions brought into force
Annual Statutes: PDF versions since 1996
Regulations: Amendments
Annual Regulations: PDF versions since 1996
Court Decisions
A-6.001, r. 6.1 - Regulation respecting the fees payable to the Institut national d’excellence en santé et en services sociaux for the scientific evaluation of a drug, stable blood product or technology for listing purposes
Schedule
Disposition versions
SCHEDULE I
(s. 1)
FEES PAYABLE FOR VARIOUS SCIENTIFIC EVALUATIONS
| Scientific evaluation | Fee | |
| Item evaluated | Type of evaluation | |
| New cellular or gene therapy | First evaluation | $95,579 per indication |
| Reevaluation | $63,719 per indication | |
| New drug with a companion diagnostic or new indication for a drug currently listed with a companion diagnostic | First evaluation | $73,278 per indication |
| Reevaluation | $38,231 per indication | |
| New drug or new indication for a currently listed drug or new stable blood product | First evaluation | $63,719 per indication |
| Reevaluation | $38,231 per indication | |
| New cutting-edge therapeutic product | First evaluation | $95,579 per indication |
| New radiopharmaceutical | First evaluation | $95,579 per indication |
| Reevaluation | $38,231 per indication | |
| New medical device directly connected with the administration of a drug | First evaluation | $63,730 per submission |
| Reevaluation | $38,231 per submission | |
| New biosimilar drug | First evaluation | $9,558 per submission |
| Subsequent evaluation (i.e., addition of an indication) | $9,558 per submission | |
| Reevaluation | $4,779 per submission | |
| New strength, new content or new form of a currently listed drug | First evaluation | $9,558 per submission |
| Reevaluation | $4,779 per submission | |
| New nutritional formula or new combination of currently listed drugs or new diagnostic agent of a currently listed non-proprietary name | First evaluation | $6,371 per submission |
| Reevaluation | $3,186 per submission | |
| New dressing | First evaluation | $12,744 per submission |
| Reevaluation | $6,371 per submission | |
| Exemption from the application of the lowest price | Any exemption request | $9,558 per submission |
SCHEDULE I
(s. 1)
FEES PAYABLE FOR VARIOUS SCIENTIFIC EVALUATIONS
| Scientific evaluation | Fee | |
| Item evaluated | Type of evaluation | |
| New cellular or gene therapy | First evaluation | $89,796 per indication |
| Reevaluation | $59,864 per indication | |
| New drug with a companion diagnostic or new indication for a drug currently listed with a companion diagnostic | First evaluation | $68,844 per indication |
| Reevaluation | $35,918 per indication | |
| New drug or new indication for a currently listed drug or new stable blood product | First evaluation | $59,864 per indication |
| Reevaluation | $35,918 per indication | |
| New cutting-edge therapeutic product | First evaluation | $89,796 per indication |
| New radiopharmaceutical | First evaluation | $89,796 per indication |
| Reevaluation | $35,918 per indication | |
| New medical device directly connected with the administration of a drug | First evaluation | $59,874 per submission |
| Reevaluation | $35,918 per submission | |
| New biosimilar drug | First evaluation | $8,980 per submission |
| Subsequent evaluation (i.e., addition of an indication) | $8,980 per submission | |
| Reevaluation | $4,490 per submission | |
| New strength, new content or new form of a currently listed drug | First evaluation | $8,980 per submission |
| Reevaluation | $4,490 per submission | |
| New nutritional formula or new combination of currently listed drugs or new diagnostic agent of a currently listed non-proprietary name | First evaluation | $5,986 per submission |
| Reevaluation | $2,993 per submission | |
| New dressing | First evaluation | $11,973 per submission |
| Reevaluation | $5,986 per submission | |
| Exemption from the application of the lowest price | Any exemption request | $8,980 per submission |
SCHEDULE I
(s. 1)
FEES PAYABLE FOR THE DIFFERENT SCIENTIFIC EVALUATIONS
| Scientific Evaluation | Fee | |
| Health technology evaluated | Type of evaluation | |
| New drug or new indication for a currently listed drug | First evaluation | $38,921 per indication |
| Reevaluation | $19,460 per indication | |
| Biosimilar | First evaluation | $7,784 per submission |
| Subsequent evaluation (i.e., addition of an indication) | $7,784 per submission | |
| Reevaluation | $3,892 per submission | |
| Subsequent entry non-biological complex drug | First evaluation | $7,784 per submission |
| Subsequent evaluation (i.e., addition of an indication) | $7,784 per submission | |
| Reevaluation | $3,892 per submission | |
| New strength(s) or new form(s) of a currently listed drug | First evaluation | $3,892 per submission |
| Reevaluation | $1,946 per submission | |
| New nutritional formula, new dressing or new combination of currently listed drugs | First evaluation | $5,189 per submission |
| Reevaluation | $2,595 per submission | |
| Diagnostic agent of a currently listed non-proprietary name | First evaluation | $2,595 per submission |
| Reevaluation | $1,297 per submission | |
| Exemption from the application of the lowest price | Any exemption request | $6,487 per submission |
| New stable blood product | First evaluation | $32,744 per submission |
| Reevaluation | $16,372 per submission | |
SCHEDULE I
(s. 1)
FEES PAYABLE FOR THE DIFFERENT SCIENTIFIC EVALUATIONS
| Scientific Evaluation | Fee | |
| Health technology evaluated | Type of evaluation | |
| New drug or new indication for a currently listed drug | First evaluation | $38,921 per indication |
| Reevaluation | $19,460 per indication | |
| Biosimilar | First evaluation | $7,784 per submission |
| Subsequent evaluation (i.e., addition of an indication) | $7,784 per submission | |
| Reevaluation | $3,892 per submission | |
| Subsequent entry non-biological complex drug | First evaluation | $7,784 per submission |
| Subsequent evaluation (i.e., addition of an indication) | $7,784 per submission | |
| Reevaluation | $3,892 per submission | |
| New strength(s) or new form(s) of a currently listed drug | First evaluation | $3,892 per submission |
| Reevaluation | $1,946 per submission | |
| New nutritional formula, new dressing or new combination of currently listed drugs | First evaluation | $5,189 per submission |
| Reevaluation | $2,595 per submission | |
| Diagnostic agent of a currently listed non-proprietary name | First evaluation | $2,595 per submission |
| Reevaluation | $1,297 per submission | |
| Exemption from the application of the lowest price | Any exemption request | $6,487 per submission |
| New stable blood product | First evaluation | $32,744 per submission |
| Reevaluation | $16,372 per submission | |
